A Retrospective, single center study comparing outcomes of patients who did and did not recieve antithymocyte globulin for Graft-Versus-Host-Disease prophylaxis in matched unrelated allogeneic hematopoietic stem cell transplant
Latest Information Update: 23 Jan 2017
At a glance
- Drugs Antithymocyte globulin (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 23 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology